AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has made a 86.43% comeback from a 12-month low price of $1.99. It was seen -4.13% lower, changing the price to $3.71, when the closing bell rang on 5/1/2019. At a recent session, the prices were hovering between $3.81 and $4. This company shares are 117.52% off its target price of $8.07 and the current market capitalization stands at $286.23M. The recent change has given its price a 9.19% lead over SMA 50 and -26.53% deficit over its 52-week high. The stock witnessed 5.4% gains, 50.81% gains and -7.48% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ACRX’s volatility during a week at 6.03% and during a month it has been found around 4.6%.

AcelRx Pharmaceuticals, Inc. (ACRX) Top Holders

Institutional investors currently hold around $57 million or 19.8% in ACRX stock. Look at its top three institutional owners: Vanguard Group Inc owns $11.13 million in AcelRx Pharmaceuticals, Inc., which represents roughly 3.89% of the company’s market cap and approximately 19.52% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 2,331,736 shares of the stock are valued at $9.02 million. The third largest holder is Laurion Capital Management Lp, which currently holds $7.53 million worth of this stock and that ownership represents nearly 2.63% of its market capitalization.

AcelRx Pharmaceuticals, Inc. 13F Filings

At the end of December reporting period, 45 institutional holders increased their position in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) by some 9,526,071 shares, 24 decreased positions by 1,802,823 and 10 held positions by 3,292,809. That puts total institutional holdings at 14,621,703 shares, according to SEC filings. The stock grabbed 27 new institutional investments totaling 5,619,457 shares while 15 institutional investors sold out their entire positions totaling 1,133,068 shares.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Insider Trades

Multiple company employees have indulged in significant insider trading. AcelRx Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director EDWARDS MARK G has acquired 19,000 shares of AcelRx Pharmaceuticals, Inc. (ACRX) in the trading session dated Mar. 12, 2019. These shares are worth $56,810 and were traded at $2.99 each. The SEC filing shows that ASADORIAN RAFFI performed a purchase of 3,647 shares. The CFO added these shares by way of transaction on Feb. 28, 2019. The company’s shares were assimilated at $2.81 per share worth to an investment of some $10,248 to the account of ASADORIAN RAFFI.

Chief Engineering Officer, Dasu Badri N, purchased 9,206 common shares of AcelRx Pharmaceuticals, Inc. (ACRX) in the open market. In a transaction dated Feb. 28, 2019, the shares were bought at an average price of $2.81, giving away a sum of $25,869. After this purchase, 113,267 common shares of ACRX are directly owned by the insider, with total stake valued at $420,221.

In the transaction dated Feb. 28, 2019, a great number of shares acquired came courtesy the CEO; Angotti Vincent J. added a total of 3,234 shares at an average price of $2.81, amounting to approximately $9,088. The insider now directly owns 257,884 shares worth $956,750.

AcelRx Pharmaceuticals, Inc. (ACRX) Analyst Guide

Several analysts have released their opinion on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.88 average brokerage recommendation [T1].